Comparative antiviral efficacies of cidofovir, trifluridine, and acyclovir in the HSV-1 rabbit keratitis model
- PMID: 9950596
Comparative antiviral efficacies of cidofovir, trifluridine, and acyclovir in the HSV-1 rabbit keratitis model
Abstract
Purpose: To determine the relative antiviral inhibitory activity of topical 1% and 0.5% cidofovir, topical trifluridine (Viroptic; Burroughs-Wellcome, Research Triangle Park, NC), and topical acyclovir (Zovirax; The Wellcome Foundation, London, UK) during a 7-day period for the treatment of herpes simplex virus type 1 (HSV-1) keratitis and HSV-1 replication in the New Zealand rabbit ocular model.
Methods: In a series of four experiments using a two-eye design, a total of 80 New Zealand rabbits were inoculated in both eyes with HSV-1 McKrae after epithelial scarification. Forty-eight hours after inoculation, the rabbits were randomly assigned to a treatment group. Five treatment groups (16 rabbits/group) were evaluated: I, 1% cidofovir, twice daily for 7 days; II, 0.5% cidofovir, twice daily for 7 days; III, 3% acyclovir ointment, five times daily for 7 days; IV, 1% trifluridine, nine times daily for 3 days, then 4 times daily for 4 days; and V, control vehicle twice daily for 7 days. HSV-1 dendritic keratitis was graded in a masked fashion by slit-lamp examination on days 2, 3, 5, 7, 9, 11, and 14. Ocular viral cultures were obtained after slit-lamp examination on days 1, 3, 5, 7, 9, 11, and 14.
Results: Compared with the control group, all four treatment groups demonstrated significantly lower viral titers, fewer HSV-1-positive eyes/total during the treatment period, lower keratitis scores, fewer eyes with keratitis/total, and a shorter time to resolution of keratitis. Within the treatment groups, the 1% and 0.5% cidofovir treatments were significantly more effective than acyclovir and trifluridine as measured by the previous viral and keratitis parameters.
Conclusions: Topical 1% and 0.5% cidofovir both appeared to be significantly more efficacious than topical trifluridine and acyclovir, during a 7-day course, in the treatment of experimental HSV-1 ocular disease in the New Zealand rabbit keratitis model.
Similar articles
-
HPMPC, a broad-spectrum topical antiviral agent, inhibits herpes simplex virus type 1 replication and promotes healing of dendritic keratitis in the New Zealand rabbit ocular model.Cornea. 1994 Nov;13(6):516-20. Cornea. 1994. PMID: 7842711
-
Trifluridine, cidofovir, and penciclovir in the treatment of experimental herpetic keratitis.Arch Ophthalmol. 1998 Jun;116(6):777-80. doi: 10.1001/archopht.116.6.777. Arch Ophthalmol. 1998. PMID: 9639447
-
Cidofovir and experimental herpetic stromal disease.Arch Ophthalmol. 1999 Jul;117(7):925-8. doi: 10.1001/archopht.117.7.925. Arch Ophthalmol. 1999. PMID: 10408458
-
Management of acyclovir-resistant herpes simplex virus.Dermatol Clin. 2003 Apr;21(2):311-20. doi: 10.1016/s0733-8635(02)00093-1. Dermatol Clin. 2003. PMID: 12757254 Review.
-
The treatment of herpes simplex virus epithelial keratitis.Trans Am Ophthalmol Soc. 2000;98:505-32. Trans Am Ophthalmol Soc. 2000. PMID: 11190039 Free PMC article.
Cited by
-
Effects of antiviral medications on herpetic epithelial keratitis in mice.Jpn J Ophthalmol. 2015 May;59(3):194-200. doi: 10.1007/s10384-015-0375-3. Epub 2015 Feb 25. Jpn J Ophthalmol. 2015. PMID: 25707352
-
Eye-related trauma and infection in dentistry.J Istanb Univ Fac Dent. 2017 Oct 2;51(3):55-63. doi: 10.17096/jiufd.60117. eCollection 2017. J Istanb Univ Fac Dent. 2017. PMID: 29114432 Free PMC article. Review.
-
Chemoselective amination of propargylic C(sp³)-H bonds by cobalt(II)-based metalloradical catalysis.Angew Chem Int Ed Engl. 2014 Jul 1;53(27):7028-32. doi: 10.1002/anie.201400557. Epub 2014 May 19. Angew Chem Int Ed Engl. 2014. PMID: 24840605 Free PMC article.
-
Putting drug resistant epithelial herpes keratitis in the spotlight: A case series.Am J Ophthalmol Case Rep. 2022 Jan 21;25:101268. doi: 10.1016/j.ajoc.2022.101268. eCollection 2022 Mar. Am J Ophthalmol Case Rep. 2022. PMID: 35112016 Free PMC article.
-
Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections.Clin Microbiol Rev. 2003 Oct;16(4):569-96. doi: 10.1128/CMR.16.4.569-596.2003. Clin Microbiol Rev. 2003. PMID: 14557287 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources